Welcome to our dedicated page for AC Immune news (Ticker: ACIU), a resource for investors and traders seeking the latest updates and insights on AC Immune stock.
AC Immune SA (ACIU) is a Swiss clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases like Alzheimer's. This page provides investors and researchers with centralized access to official news, financial disclosures, and scientific developments directly from the company.
Key resources include earnings reports, clinical trial updates, strategic collaborations, and regulatory milestones. Stay informed on ACIU's progress in developing diagnostic tools and therapies targeting protein misfolding pathologies through its proprietary platforms.
Content spans pipeline advancements, peer-reviewed research highlights, and material business events. Bookmark this page to efficiently track ACIU's contributions to neuroscience innovation and make data-driven decisions based on verified company communications.
AC Immune will host a Key Opinion Leader webinar focused on the early diagnosis and prevention of Alzheimer’s disease on April 18, 2023, at 10:30 AM EDT / 4:30 PM CEST. CEO Andrea Pfeifer will kick off the session, introducing speakers Dr. Kaj Blennow and Dr. Giovanni Frisoni, who will discuss advancements in Alzheimer’s detection and the potential of therapeutic vaccines. The presentations will detail AC Immune's Precision Medicine approach and highlight clinical-stage vaccines targeting amyloid-beta and phosphorylated Tau. A Q&A session will follow. Interested participants can register here.
AC Immune announced ten presentations at the AD/PD™ 2023 conference in Gothenburg, Sweden, from March 28 to April 1, 2023. The company is focused on precision medicine for neurodegenerative diseases, highlighting progress in Alzheimer's and Parkinson's treatments. Chief Medical Officer Johannes Streffer will discuss immunotherapies at the event. The CEO emphasized the advancements in their vaccine pipeline and the potential for significant market impact. AC Immune's pipeline includes first- and best-in-class assets, with several candidates in Phase 2 and 3 clinical trials, underscoring their commitment to innovative treatments.
AC Immune reported its 2022 financial results showcasing a cash position of CHF 122.6 million, providing runway into Q3 2024. The company recorded CHF 3.9 million in contract revenues, a significant increase from zero in the prior year. R&D expenditures decreased to CHF 60.3 million, primarily due to advancements in clinical studies for ACI-24.060. The net loss was CHF 70.8 million, a slight improvement from CHF 73.0 million in 2021. Looking ahead, the company anticipates a cash burn of CHF 65 to CHF 75 million for 2023, and milestones for its anti-amyloid and anti-Tau vaccine developments are set for 2023.
AC Immune (NASDAQ: ACIU) has announced a press release to report its full year 2022 financial results and provide a corporate update on March 16, 2023, at 7:00 am ET. After the announcement, management will be available for one-on-one calls with investors and analysts to discuss the results and outlook for 2023. The company focuses on precision medicine for neurodegenerative diseases, utilizing its two technology platforms, SupraAntigen® and Morphomer®, and has a robust pipeline with ten therapeutic and three diagnostic candidates.
FAQ
What is the current stock price of AC Immune (ACIU)?
What is the market cap of AC Immune (ACIU)?
